Depression Treatment: Therapy, Medication, and Other Options
Author: Angela Bogdanova · Published: October 8, 2026 · Editorial Policy
Research cluster: Depression & Depressive Disorders · Written by Artificial Sapiens
Depression is treatable, and an effective treatment plan is built around the type and severity of depression, functional impairment, safety, previous care, medical history, access, and the person's preferences. Evidence-based options include structured psychotherapy, antidepressant medication, and their combination. Depending on severity and response, care may also involve exercise programs, guided self-help, collaborative medical follow-up, brain stimulation, or specialized interventions for difficult-to-treat illness. The goal is meaningful recovery: relief of symptoms, restoration of everyday functioning, sustained remission, and prevention of future episodes. These choices are described in the American College of Physicians' clinical guideline, NICE guidance for adults, and the VA/DoD major depressive disorder guideline.
The first treatment decision is a clinical one: determine whether the person has a depressive disorder, whether the episode belongs to a unipolar or bipolar course, whether urgent safety needs exist, and what level of support is practical. A person with milder symptoms may begin with guided self-help or a structured psychotherapy; another with severe, disabling, recurrent, or psychotic depression may need medication, combined treatment, or specialist care from the beginning. A satisfactory plan is reviewed and adjusted rather than continued unchanged when it is ineffective or poorly tolerated.
For related clinical context, see Depression: Symptoms, Causes, Diagnosis, and Treatment.
I. What counts as treatment for depression?
Treatment for depression encompasses interventions intended to reduce clinically significant depressive symptoms and impairment, restore functioning, and lower the likelihood of relapse or recurrence. Psychotherapy and medication have the largest first-line evidence bases for major depressive disorder. Additional approaches can be important when chosen for the particular person's circumstances and evidence-based indication.
A depressed mood, an isolated symptom such as fatigue, a positive questionnaire result, a major depressive episode, and a diagnosis of major depressive disorder are different clinical concepts. Treatment decisions depend on the actual presentation and its causes. A screening score can support assessment and monitor change, but it cannot independently establish a diagnosis or prescribe treatment. As the National Institute of Mental Health explains, treatment planning takes account of individual needs and clinical evaluation.
For practical purposes, an effective plan has five components: assessment; an agreed treatment choice; access to competent delivery; monitoring of benefits, adverse effects and functioning; and a continuation or relapse-prevention strategy. Support with sleep, physical activity, work, education, finances, housing, relationships, and medical problems can be part of this plan when those needs are relevant.
II. How doctors and patients choose the first treatment
1. Less severe depression
For milder or less severe depression, options often include guided self-help grounded in cognitive behavioral principles, behavioral activation, structured psychotherapy, and exercise adapted to a person's capacity. Active monitoring may be appropriate when symptoms are recent and comparatively mild, provided the person agrees and has a specific follow-up plan. A plan to return only if things become unbearable is not active monitoring.
The NICE guideline generally advises against routinely offering an antidepressant as a first-line choice for less severe adult depression unless that is the person's informed preference, while the ACP guideline suggests cognitive behavioral therapy for mild major depressive disorder. The individual decision still considers episode history, impairment, availability, medical factors, and previous response.
2. Moderate depression
For moderate major depressive disorder, evidence-based psychotherapy and a second-generation antidepressant are both established initial options. Combining them may be appropriate when symptoms, prior episodes, complexity, patient preference, or available resources favor doing so. ACP offers either cognitive behavioral therapy or a second-generation antidepressant as initial monotherapy for moderate-to-severe major depression and suggests combination therapy as an alternative, with a lower certainty rating for that specific combination recommendation. See the ACP recommendations.
3. Severe depression
Severe depression may cause extensive impairment in eating, sleeping, self-care, relationships, or work, sometimes with marked agitation, psychomotor slowing, psychotic features, or an acute risk of self-harm. It warrants timely clinical assessment, a higher level of support when indicated, and frequent follow-up. Medication with psychotherapy is often considered, and urgent specialist options may be needed in selected cases. NICE addresses specialist referral and the role of electroconvulsive therapy for severe depression.
The categories mild, moderate, and severe guide decisions, but clinical urgency also depends on function, medical status, agitation, psychosis, suicidality, self-neglect, support at home, and access to care. No single questionnaire threshold captures all of these considerations.
III. What must be checked before treatment starts?
A clinician takes a history of low mood or loss of interest, sleep and appetite changes, energy, concentration, guilt, psychomotor change, duration, functioning, prior episodes, medical illnesses, current medications, substances, and family history. The assessment also considers thyroid disease, anemia when indicated, sleep disorders, substance-related effects, and other explanations for depression-like symptoms. Tests are ordered for clinical reasons rather than as a universal depression panel.
History of mania, hypomania, or mixed symptoms requires particular attention. Episodes of elevated or unusually irritable mood with increased energy, reduced need for sleep, accelerated thinking, or impulsive activity may indicate bipolar illness. Treatment of bipolar depression follows a different evidence base, and antidepressant monotherapy can present important risks when bipolar disorder goes unrecognized. The VA/DoD MDD guideline places diagnostic clarification and clinical assessment before the choice of treatment.
Clinicians also ask about hallucinations, fixed delusional beliefs, severe agitation, catatonic signs, substance use, and suicide-related thinking. Psychotic depression and bipolar depression call for specialized treatment decisions. Bereavement, occupational burnout, and adjustment difficulties can coexist with depressive disorders but each requires attention to its own context and diagnostic criteria. These distinctions influence care rather than being labels assigned from an online score.
IV. Psychotherapy for depression
Psychotherapy treats depression through a structured professional relationship and techniques that target patterns maintaining distress and impairment. Evidence is strongest for several specific, competently delivered approaches, rather than for an undifferentiated category called talk therapy. A 2023 meta-analysis of 409 randomized trials involving 52,702 participants found cognitive behavioral therapy effective for depression and examined how outcomes compared with other psychotherapies, pharmacotherapy, and combinations.
1. Cognitive behavioral therapy (CBT)
CBT works with depressive thinking patterns, avoidance, reduced activity, and behaviors that sustain low mood. Sessions commonly involve collaboratively identifying obstacles, practicing new skills, examining interpretations, and applying changes between appointments. It can be delivered individually, in groups, or through appropriately supported digital formats. Structure and therapeutic quality matter more than whether a session takes place in a physical office.
CBT is a first-line option across guidelines, especially when the person prefers a skills-based psychological approach or wants to reduce the risk of future episodes through ongoing coping strategies. The Cuijpers and colleagues meta-analysis supports its efficacy while also showing why average study effects should not be interpreted as a guaranteed individual outcome.
2. Behavioral activation
Behavioral activation focuses on the feedback loop between depression, withdrawal, reduced sources of reward, and difficulties initiating action. The therapist helps a person identify meaningful, achievable activities, reduce avoidance, address barriers, and gradually rebuild participation in everyday life. It is particularly useful when low motivation and inactivity are prominent; it does not require a person to feel motivated before beginning a carefully scaled step.
NICE lists behavioral activation among the evidence-based psychological options for adult depression, with selection reflecting preferences, severity, and availability. NICE NG222.
3. Interpersonal psychotherapy (IPT)
IPT examines depression in relation to interpersonal disputes, transitions in roles, complicated changes in relationships, and social isolation. It helps identify communication patterns, clarify needs, and strengthen supportive connections. A person facing a major relationship or role transition may find IPT particularly relevant. The NIMH depression treatment overview recognizes IPT as an evidence-based option.
4. Other structured psychological treatments
Problem-solving therapy, some short-term psychodynamic approaches, and mindfulness-based cognitive therapy can have appropriate roles depending on symptoms, chronicity, relapse history, available expertise, and therapeutic goals. Mindfulness-based cognitive therapy is particularly relevant to some relapse-prevention plans rather than as a universal substitute for acute treatment. Couples-based approaches may be useful when relationship difficulties are contributing to depression and the partner's involvement is safe and welcome. The comparative options and qualifications are described in NICE guidance.
A therapist's credentials, the evidence behind the chosen protocol, the collaborative treatment goals, and the ability to monitor progress should all be discussed. Therapy is an active clinical intervention; its content, quality, dose, and fit matter.
V. Antidepressant medication for depression
Antidepressants can reduce symptoms of major depressive disorder, especially when depression is moderate or severe, recurrent, persistent, or insufficiently responsive to psychotherapy alone. They are also sometimes selected as initial treatment because of previous personal benefit, availability, or informed preference. A large network meta-analysis of 21 antidepressants found that all included drugs were more effective than placebo on average in acute adult major depression, with meaningful differences in acceptability and adverse effects.
1. Common medication families
Selective serotonin reuptake inhibitors (SSRIs), such as sertraline, escitalopram, and fluoxetine, are frequently used because clinicians are familiar with their effectiveness, interactions, and safety considerations. Serotonin–norepinephrine reuptake inhibitors (SNRIs), including venlafaxine and duloxetine, are additional options. Other agents include bupropion, mirtazapine, and vortioxetine. Tricyclic antidepressants and monoamine oxidase inhibitors may be useful in selected situations but require particular attention to interactions, precautions, and overdose risk. The NIMH medication overview outlines major antidepressant families.
A medication is selected by considering previous benefit, coexisting conditions, sleep and appetite concerns, sexual adverse effects, weight changes, fatigue, anxiety, blood-pressure considerations, interacting drugs, pregnancy or breastfeeding circumstances, overdose risk, and the person's priorities. There is no universally best antidepressant for every adult.
2. When should medication start helping?
Some effects on sleep, anxiety, or appetite may occur earlier than the full antidepressant benefit. A clinically meaningful response commonly requires several weeks, and prescribers review symptoms and adverse effects rather than waiting indefinitely. The NIMH describes a typical 4–8-week period to assess full effects, while NICE advises an early follow-up and more rapid assessment for young adults and those with increased suicide risk.
An appropriate trial involves a suitable medication, dose, duration, adherence, and follow-up. Persistent symptoms are a reason to reassess the plan, including diagnosis and safety, rather than to assume that the person cannot recover.
3. Side effects and physical risks
Potential adverse effects include nausea, gastrointestinal changes, headaches, sleep disturbance, sexual dysfunction, emotional blunting for some people, sweating, agitation, and weight changes. Particular agents carry additional risks, including blood-pressure effects, falls or electrolyte disturbances in vulnerable patients, interactions with other medications, and toxicity in overdose. The pattern depends on the drug, dose, the individual's health, and concurrent treatments. Clinicians discuss expected benefits and specific harms before prescribing. See NIMH and NICE.
Antidepressant labeling includes a warning about an increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults in short-term trials. Patients and caregivers should watch for clinical deterioration, agitation, or unusual behavioral changes, particularly when starting or changing treatment. This is a reason for active monitoring and timely professional contact, not a reason to abandon medically indicated care without advice. The AAP adolescent depression guideline discusses this requirement.
4. Stopping antidepressants and withdrawal
Antidepressants should be reduced through an individualized plan developed with the prescriber. Abrupt stopping, missed doses, or rapid dose reduction can produce dizziness, nausea, sensory disturbances, insomnia, agitation, anxiety, and other discontinuation symptoms. Severity and duration vary; some people require slower reductions over a longer period. NICE NG222 gives specific principles for collaborative, staged tapering.
Withdrawal symptoms, return of depression, and new illness can overlap. Timing, symptom quality, treatment history, and clinical review help distinguish them. A 2025 JAMA Psychiatry meta-analysis found discontinuation-related symptoms on average, with important variability and methodological limitations. The precise taper should be personalized; online dose schedules cannot account for individual risk and available formulations.
VI. Is therapy or medication more effective?
Both structured psychotherapy and antidepressants are effective on average, and neither has an unconditional advantage for every person, outcome, or severity level. CBT may be preferred when a person wants an approach emphasizing psychological skills and potential durable benefits. Medication may be chosen because of severity, previous response, access barriers, or preference. Combining medication and psychotherapy can be appropriate when initial treatment is insufficient or when a comprehensive plan fits the clinical presentation.
Comparison requires attention to which population was studied, baseline severity, definition of response, follow-up duration, treatment quality, withdrawal from treatment, and adverse events. The ACP guideline and Cuijpers et al. support individualized treatment and caution against presenting a single winner from aggregated results.
Combined treatment can be especially reasonable for more severe or recurrent illness and for people who want both symptom reduction and practical psychological skills. It also costs time, money, or organizational effort, so the expected benefit must be discussed rather than assumed.
VII. Self-help, physical activity, and everyday support
Regular movement, protected sleep opportunities, supportive relationships, manageable routines, nutrition, reduced substance-related harm, and assistance with material stressors can reinforce treatment and recovery. Their contribution depends on feasibility; depression often makes routine tasks unusually difficult. A care plan should begin from the person's present capacity, not from an ideal schedule.
A 2024 BMJ network meta-analysis of 218 trials involving 14,170 participants found that activities including walking or jogging, yoga, and resistance training improved depressive symptoms versus active controls on average, though the evidence varied in certainty and trial quality. Exercise can be a treatment option for some people and an adjunct for others. It is adapted to medical conditions, disability, safety, preferences, and accessibility.
Guided self-help grounded in CBT or behavioral activation offers more structure than unsupervised wellness tips. Clinician-supported online programs and teletherapy may improve access; their evidence depends on the program, degree of guidance, population, and outcomes studied. A general-purpose AI chatbot or a commercial companion should not automatically be described as clinically validated depression therapy on the basis of research on structured interventions. The distinction matters when digital tools are used alongside professional care.
Lifestyle support does not replace indicated treatment or urgent assessment for severe depression, psychosis, mania, or immediate danger. Supportive actions work best when paired with realistic clinical follow-up and practical accommodations.
VIII. Advanced and specialist treatments
1. Electroconvulsive therapy (ECT)
ECT is an established medical intervention in which a controlled electrical stimulus is delivered under anesthesia with muscle relaxation to produce a therapeutic seizure. It can be considered for severe depression requiring rapid improvement, for some people who previously benefited, and for selected presentations where other treatment has failed or is unsuitable. It is particularly relevant to specialist management of severe psychotic depression and certain life-threatening circumstances. NICE NG222 specifies indications, consent, monitoring, and follow-up.
ECT carries anesthesia-related risks and can cause headaches, confusion, and memory difficulties, which should be discussed in informed consent. Modern ECT protocols differ in electrode placement and stimulation parameters; clinical response and cognitive effects are monitored. ECT is followed by continuation strategies because improvement after an acute course does not eliminate the risk of future episodes.
2. Transcranial magnetic stimulation (TMS)
Repetitive transcranial magnetic stimulation applies magnetic pulses to targeted brain regions while the patient is awake. It is a noninvasive specialist treatment with evidence for depression, especially after inadequate response to standard care. It typically requires repeated sessions and assessment of seizure risk, implants or other contraindications, headache, and tolerability. Selection and protocol depend on local regulatory approval and clinical expertise. The VA/DoD guideline addresses TMS as an advanced option.
TMS and ECT have different logistics, evidence patterns, and side-effect profiles. They should not be treated as interchangeable merely because both involve brain stimulation.
3. Ketamine and esketamine
Ketamine has shown rapid antidepressant effects in some patients with treatment-resistant depression. Intravenous racemic ketamine used for psychiatric depression is an off-label treatment in the United States and requires appropriate clinical oversight. Intranasal esketamine, marketed as Spravato, has an FDA-approved indication for adult treatment-resistant depression and is administered under a restricted clinical safety program. The current U.S. prescribing information states that Spravato may be used for treatment-resistant depression either alone or with an oral antidepressant, reflecting the expanded U.S. monotherapy indication in 2025.
For adults with major depressive disorder and acute suicidal ideation or behavior, the label describes a separate indication for depressive symptoms with an oral antidepressant; it expressly states that effectiveness in preventing suicide has not been established. It does not replace hospitalization when clinically necessary. Because of sedation, dissociation, respiratory depression, transient blood-pressure changes, and misuse concerns, treatment requires supervised administration and post-dose monitoring under the REMS program. See the official DailyMed label.
Trials comparing ketamine with ECT differ by population and design. A 2023 randomized trial in nonpsychotic treatment-resistant depression supported noninferiority on its specified response endpoint in that setting, while a 2024 systematic review did not establish noninferiority across its pooled studies and found evidence favoring ECT among inpatients. Neither result justifies a universal treatment ranking.
4. Other interventions
Vagus nerve stimulation is used in selected specialist settings and requires individualized discussion of eligibility, risks, and evidence. Light therapy may be helpful for some people with a seasonal pattern, with attention to bipolar risk and clinical evaluation. Psilocybin-assisted approaches remain investigational for depression in the United States as of this review; promising trial results are not equivalent to routine clinical authorization or established long-term safety. Supplements, herbal preparations, and unregulated ketamine products can carry medical and interaction risks. The VA/DoD guideline and NICE recommendations support condition-specific evaluation rather than a menu of presumed equivalent interventions.
IX. What if the first treatment does not work?
Partial improvement, persistent impairment, worsening, and intolerable side effects require different responses. A clinician reviews diagnosis, duration, adherence, medication interactions, psychotherapy fidelity and intensity, sleep and medical problems, substance use, psychosocial adversity, and current safety. This is also an opportunity to revisit possible bipolar illness or psychotic symptoms.
Evidence-based next steps may include adjusting an antidepressant when appropriate, switching to a different medication, changing or adding psychotherapy, combining medication and therapy, or specialist augmentation. Some augmentation options, such as adding certain second-generation antipsychotic medications or lithium, require substantial monitoring of metabolic, neurologic, renal, thyroid, or other risks. Shared decisions are guided by ACP recommendations and the further-line sections of NICE NG222.
Treatment-resistant depression commonly refers to an inadequate response to at least two adequately selected and delivered antidepressant trials, though definitions vary across research and care systems. Inadequate dose, too little time, missed treatment, or an incorrect diagnosis can create apparent resistance. A resistance label calls for reassessment and a more specialized plan; it is not a prediction that improvement is impossible.
X. Treatment in particular clinical presentations
Persistent or recurrent depression
Persistent depressive disorder, repeated major depressive episodes, and depression with residual symptoms can require longer-term strategies, careful attention to functioning, and relapse prevention. A chronic course may justify combining modalities or continuing effective care for longer, depending on response and risk. NICE provides recommendations for chronic depression and prevention of relapse.
Depression with psychotic features
When depression occurs with hallucinations or delusions, specialist psychiatric assessment is important. Treatment may involve an antidepressant with an antipsychotic medication, and ECT may be considered in severe circumstances. Monitoring and specialist follow-up are essential. The diagnostic specifier is clinically meaningful and should not be mistaken for ordinary pessimistic thinking. See NICE's psychotic-depression recommendations.
Seasonal, melancholic, and atypical presentations
A seasonal pattern is a specifier used when episodes show a characteristic repeated time-of-year course; it is not an all-purpose name for winter sadness. Melancholic and atypical features are depressive episode specifiers with defined clinical characteristics. Their presence can guide further assessment and clinical planning, but no single colloquial symptom profile automatically determines one medication or treatment.
Children and adolescents
Young people require developmentally appropriate assessment, involvement of caregivers when safe and appropriate, attention to school and family functioning, and an explicit safety and follow-up plan. Evidence-based psychotherapy is central; medication decisions take account of age, licensing, illness severity, specialist expertise, monitoring, and the FDA suicidality warning. Recommendations for adults must not be transferred wholesale to children. See AAP GLAD-PC Part I and Part II.
Older adults, medical illness, and reproductive contexts
For older adults, clinicians weigh comorbid disease, cognition, polypharmacy, medication interactions, fall risk, and social isolation. Depression accompanied by chronic illness may benefit from coordinated management of both conditions. Pregnancy, postpartum depression, and reproductive mood conditions require specialized, context-specific assessment of medication safety and psychological care. A broad article about adult depression is a starting point, not an individualized perinatal prescribing guide.
XI. How progress is measured and when treatment continues
Treatment response means meaningful improvement; remission means symptoms have fallen below a specified clinical threshold; recovery describes sustained improvement across time and functioning. Relapse refers to symptom return within the same course before recovery has been sustained, whereas recurrence refers to a new episode after recovery. Different studies use different operational definitions, so percentages should always be interpreted in context.
Clinicians track symptom change, functioning, sleep, social participation, treatment adherence, adverse effects, safety, and goals important to the person. Patient-reported scales can help monitor progress, but diagnosis and medical decisions require clinical interpretation. An early review establishes whether the person can tolerate the plan and whether urgent changes are needed. At subsequent appointments, the clinician and patient decide whether to continue, adapt, combine, or change treatment.
Continuation treatment after remission can reduce relapse risk. NICE advises that antidepressants are commonly taken for at least six months, including after symptoms have remitted, with a longer course considered when prior episodes or other risk factors justify it. Decisions about long-term medication balance prevention benefits against side effects and withdrawal concerns. NICE relapse-prevention guidance.
XII. What shared decision-making looks like
Shared decision-making involves a clinician explaining reasonable choices and the person describing goals and concerns. Useful questions include: What diagnosis and severity are being treated? What is the evidence for this option? What benefits are realistic and when will we reassess? What adverse effects, interactions, or discontinuation problems should I watch for? Which outcome would mean that treatment is helping? What is the plan if it does not help? What will treatment cost, how often are appointments needed, and which professional should be contacted between visits?
Access is part of treatment quality. Insurance networks, geographic distance, language, disability accommodations, transportation, availability of qualified clinicians, and medication affordability can influence what is feasible. Primary care clinicians, psychiatrists, psychologists, therapists, pharmacists, and care coordinators may contribute to a collaborative plan. Digital delivery can widen access when the service itself is appropriate and evidence based.
A person supporting someone with depression can help arrange an appointment, reduce logistical burdens, offer practical companionship, and notice significant deterioration. Respectful support does not involve pressuring the person to disclose everything or prescribing treatment on their behalf.
XIII. When to seek urgent help
Immediate assessment is appropriate when a person is at risk of acting on suicidal thoughts, cannot maintain basic safety, experiences severe psychotic symptoms, develops mania, is unable to eat or drink adequately, or has a rapidly deteriorating condition. In the United States, call 911 for immediate danger or 988 for suicide-related crisis support. Elsewhere, contact local emergency services or an urgent mental-health service. A person in immediate danger should not be left alone when it is safe to stay with them, and access to lethal means should be reduced while professional help is being obtained. The NIMH depression resource addresses urgent help and treatment pathways.
XIV. Frequently asked questions
Can depression be treated without medication?
Yes. Evidence-based psychotherapy can be an appropriate primary treatment for some people, especially with less severe depression or a preference for psychological care. Guided self-help and structured exercise programs can also play a role. Severe, recurrent, psychotic, or high-risk depression may require medication or specialist intervention. ACP.
Is CBT better than antidepressants?
There is no universal winner. Both are supported by research, and the preferable choice depends on severity, clinical history, access, adverse effects, and values. Combining treatments may help in selected circumstances. Cuijpers et al..
How long does treatment for depression take?
Psychotherapy often spans multiple sessions over weeks or months. Antidepressants usually require several weeks before the full effect can be judged. Continuation care may extend for months or longer according to risk and response. Progress is assessed at agreed intervals, rather than predicted from a fixed timeline. NIMH.
What if I feel worse after starting medication?
New agitation, severe adverse effects, worsening depression, unusual mood elevation, or suicidal thoughts require prompt contact with a clinician; immediate danger requires emergency help. Do not adjust or stop a prescribed medicine abruptly without medical advice unless emergency professionals direct otherwise. NICE.
Are antidepressants addictive?
Antidepressants do not produce intoxication or compulsive reward-seeking in the way addictive substances can. Physical adaptation and discontinuation symptoms can nevertheless occur, and stopping may require individualized tapering. NICE.
Is there a blood test for depression?
No blood test by itself confirms major depressive disorder. Clinicians may request tests to assess medical explanations or treatment safety when the history or examination warrants them. NIMH.
Can exercise cure major depression?
Exercise programs can reduce depressive symptoms on average, but responses vary and study quality differs. Some people can use exercise as an initial structured treatment; others need psychotherapy, medication, or specialist care as well. Noetel et al..
Is TMS the same as ECT?
No. TMS uses magnetic stimulation while the person is generally awake, whereas ECT involves a medically induced seizure under anesthesia. Indications, protocols, risks, and logistics differ. VA/DoD.
Is esketamine available without an oral antidepressant?
For adult treatment-resistant depression in the United States, the current prescribing information permits Spravato as monotherapy or with an oral antidepressant. Another labeled indication involving acute suicidal ideation or behavior has different conditions and does not establish suicide-prevention efficacy. Administration requires a certified clinical setting and monitoring. DailyMed.
What is the difference between relapse and recurrence?
Relapse is the return of depressive symptoms before sustained recovery from the same course; recurrence is a new depressive episode following a period of recovery. Definitions vary in research, and follow-up decisions consider symptoms, functioning, and history. NICE.
What does treatment-resistant depression mean?
It generally describes depression with inadequate improvement after at least two adequate antidepressant trials, while exact definitions vary. Clinicians also check whether the original diagnosis and the prior trials were appropriate. Specialty treatments remain available. NIMH.
Can an AI chatbot replace depression treatment?
General-purpose AI chatbots and AI companions are different from purpose-built, clinically evaluated therapeutic programs. Evidence about one class should not be transferred to another. People can find digital support meaningful, but a chatbot cannot independently provide the diagnostic, prescribing, safety, and continuity responsibilities of a qualified mental-health service. For significant impairment, seek an evidence-based assessment and treatment plan.
XV. A practical next-step pathway
If depressive symptoms are persistent or are interfering with ordinary life, arrange an assessment with a primary care clinician or qualified mental-health professional. Describe the duration of symptoms, what has changed in daily function, medication and substance use, prior mental-health history, and any safety concerns. Ask about an evidence-based psychotherapy, medication, combined treatment, or another supported option appropriate to the clinical picture. Agree on follow-up and what to do if symptoms worsen.
If treatment is already underway, review actual benefits and adverse effects at the agreed appointment. Meaningful care includes making changes when necessary and planning how improvements will be sustained. In all cases, urgent safety needs take priority over routine scheduling.
Related Articles
References
American Academy of Pediatrics. (2018). Guidelines for Adolescent Depression in Primary Care (GLAD-PC), Parts I and II. Part I and Part II.
Cipriani, A., et al. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: Systematic review and network meta-analysis. The Lancet. https://doi.org/10.1016/S0140-6736(17)32802-732802-7).
Cuijpers, P., et al. (2023). Cognitive behavior therapy versus control conditions, other psychotherapies, pharmacotherapies and combined treatment for depression: A meta-analysis of 409 trials. World Psychiatry. https://doi.org/10.1002/wps.21069.
DailyMed. (2026). Spravato (esketamine) nasal spray: U.S. prescribing information. Official drug label.
Henssler, J., et al. (2024). Incidence of antidepressant discontinuation symptoms: A systematic review and meta-analysis. The Lancet Psychiatry. https://doi.org/10.1016/S2215-0366(24)00133-000133-0).
Kalfas, M., et al. (2025). Incidence and nature of antidepressant discontinuation symptoms: A systematic review and meta-analysis. JAMA Psychiatry. https://doi.org/10.1001/jamapsychiatry.2025.1362
National Institute for Health and Care Excellence. (2022). Depression in adults: Treatment and management (NG222). Recommendations.
National Institute of Mental Health. (n.d.). Depression. Public health overview.
National Institute of Mental Health. (n.d.). Mental health medications. Official overview.
Noetel, M., et al. (2024). Effect of exercise for depression: Systematic review and network meta-analysis of randomized controlled trials. BMJ. https://doi.org/10.1136/bmj-2023-075847.
Petrucci, A. B. C., et al. (2024). Ketamine versus electroconvulsive therapy for major depressive episode: An updated systematic review and non-inferiority meta-analysis. Psychiatry Research. https://doi.org/10.1016/j.psychres.2024.115994.
Qaseem, A., et al. (2023). Nonpharmacologic and pharmacologic treatments of adults in the acute phase of major depressive disorder: A living clinical guideline. Annals of Internal Medicine. PubMed.
U.S. Department of Veterans Affairs & U.S. Department of Defense. (2022). Management of major depressive disorder: Clinical practice guideline. VA/DoD guideline.
World Health Organization. (2023). Antidepressants for adults with depressive episode/disorder. WHO mhGAP recommendation.